Daudi Cells人Burkitt's淋巴瘤细胞实验室复

"Daudi Cells人Burkitt's淋巴瘤细胞实验室复苏|STR图谱
LS1034 Cells人结肠腺癌细胞保种中心|STR图谱
H9 Cells人T淋巴细胞保种中心|STR图谱
HT-1197 Cells人膀胱癌细胞保种中心|STR图谱
4T1-RFP Cells小鼠乳腺癌细胞保种中心|STR图谱
M-1 [Mouse kidney] Cells小鼠肾集合管细胞保种中心|STR图谱
UMR-106 Cells大鼠骨肉瘤细胞保种中心|STR图谱
SW480(DM) Cells人结肠癌细胞保种中心|STR图谱
MUG-Chor1 Cells人骶骨脊索瘤细胞保种中心|STR图谱
物种来源：Daudi Cells人Burkitt's淋巴瘤细胞实验室复苏|STR图谱来源于人源、鼠源等其它物种来源
生长特性：Daudi Cells人Burkitt's淋巴瘤细胞实验室复苏|STR图谱悬浮生长
健康监护体系是保障细胞茁壮成长的关键防线。实验室中的细胞培养箱就像配备恒温恒湿的婴儿房，需要24小时监控温度、CO2浓度和湿度。当培养液出现云雾状浑浊，这相当于婴儿的异常哭闹，可能是细菌污染的征兆，需要立即进行""急诊处理""：更换新鲜培养基并加入双抗。对于贴壁细胞出现的""发育迟缓""（增殖缓慢、形态改变），经验丰富的技术人员会像儿科医生一样""对症下药""：先用胰酶进行""消化调理""，再以富含营养的新培养基""调理肠胃""，必要时加倍补充细胞因子这个""生长激素""。而悬浮细胞群体若出现生长停滞，则需谨慎调整""饮食配方""，优先补充血清和特定细胞因子，就像为厌食的幼儿准备开胃辅食。
细胞经过多次传代后，建立了稳定的体外培养模型且可稳定增殖。这些微小的生命单元在培养瓶中生生不息，恰似一支训练有素的军团，为科学家们科研实验提供着源源不断的创新灵感与技术支持。其价值不仅体现在当前广泛的应用中，更在于它为未来生命科学研究提供的可能性。随着技术的进步和对这一细胞系认识的深入，必将在更多领域展现其独特优势。研究人员在使用时应当充分了解其特性，合理设计实验，并注意细胞培养的质量控制，以确保研究结果的可靠性和可重复性。
形态特性：Daudi Cells人Burkitt's淋巴瘤细胞实验室复苏|STR图谱淋巴母细胞样
换液周期：Daudi Cells人Burkitt's淋巴瘤细胞实验室复苏|STR图谱每周2-3次
产品包装：复苏发货：Daudi Cells人Burkitt's淋巴瘤细胞实验室复苏|STR图谱T25培养瓶(一瓶)或冻存发货：1ml冻存管(两支)
细胞如同娇嫩的花朵，在运输途中若遭遇温度骤变或剧烈颠簸，便会遭受难以愈合的创伤。特别是那些沉睡在冰晶宫殿中的冷冻细胞，倘若缺少干冰这位忠诚的守护者，或是温度调控稍有不慎，便会像晨露遇见烈日般迅速失去生机。因此，务必选择值得托付的运输方式，当细胞抵达时，请第一时间轻抚它的""外衣""检查是否完好，并确认干冰这位守护者是否仍在坚守岗位。
瓶装500ml血清的解冻需要采用逐步升温的""阶梯式解冻法""，这是保证血清质量的关键步骤。具体操作流程如下：首先将血清从–20℃或–70℃转移至4℃冰箱，缓慢溶解24小时。这一低温过渡阶段可以让血清中的各种成分逐渐适应温度变化，避免突然的温度波动导致蛋白质变性。待血清完全溶解后，再将其移至室温环境使其完全解冻。在解冻过程中，需要每隔2-3小时轻轻摇晃瓶身，使血清各部分的温度和成分均匀分布，这一操作能显著减少沉淀物的形成。但需特别注意摇晃力度，避免产生气泡，因为气泡可能导致血清中的蛋白质变性。
背景信息：Daudi Cells人Burkitt's淋巴瘤细胞实验室复苏|STR图谱１９６７年，该细胞系KleinE和KleinG建系，源于一名１６岁患有Burkitt＇s淋巴瘤的黑人男性，beta-２-微球蛋白阴性，表达EBNA,VCA，sIg。该细胞携带EB病毒，是一个典型的B淋巴母细胞系，可用于白血病发病机制的研究。
传代比例：1:2-1:4(Daudi Cells人Burkitt's淋巴瘤细胞实验室复苏|STR图谱首次传代建议1:2)
来源说明：Daudi Cells人Burkitt's淋巴瘤细胞实验室复苏|STR图谱主要来源ATCC、ECACC、DSMZ、RCB等细胞库
定期检测细胞培养液的无菌状态是必要的。可以通过以下方法进行检测：污染的培养液通常会出现浑浊、变色或沉淀物增多的现象。定期在显微镜下观察细胞状态，如发现异常漂浮物或细胞形态改变，可能提示污染。取少量培养液接种于细菌或真菌培养基中，37°C培养24-48小时，观察是否有微生物生长。
细胞培养技术犹如一门精密的育儿艺术。那些形态优美、增殖迅猛、纯度卓越且功能性强大的细胞系，往往是科研人员倾注心血培育的""明星宝宝""。这个将生命科学与人伦亲情巧妙融合的过程，揭示了细胞培养与育儿之间惊人的相似性——都需要科学的方法、细致的观察和无微不至的呵护。细胞传代技术则反映了生命延续的哲学。当培养瓶中的细胞生长至80%融合度时，就需要进行""分房睡""处理——用胰酶温和消化后按比例传代。这个看似简单的过程实则暗藏玄机：消化过度会导致细胞""外伤""，消化不足则造成""分离焦虑""。经验表明，保持1:2至1:4的传代比例最利于细胞适应新环境（经验心得：首次传代建议1:2），就像逐步扩大幼儿的活动空间。
SCC-7 Cells小鼠鳞状癌细胞保种中心|STR图谱
HCT116-luc Cells人结肠癌细胞保种中心|STR图谱
C3H/10T1/2 clone 8 Cells小鼠胚胎成纤维细胞保种中心|STR图谱
TE-7 Cells人食管癌细胞保种中心|STR图谱
CCLP1 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明书部分;形态特性：详见产品说明书;相关产品有：HS0578T细胞、P3X63-Ag8.653细胞、F442-A细胞
CCLP1 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明书部分;形态特性：详见产品说明书;相关产品有：HS0578T细胞、P3X63-Ag8.653细胞、F442-A细胞
OUMS-27 Cells;背景说明：软骨肉瘤；男性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明书;相关产品有：KYSE270细胞、H774细胞、B-cell Acute Lymphoblastic Leukemia-1细胞
GM21482 Cells(提供STR鉴定图谱)
HAP1 MAP2K7 (-) 2 Cells(提供STR鉴定图谱)
G422-Luc Cells小鼠脑神经胶质母细胞瘤瘤细胞保种中心|STR图谱
ND7/23 Cells大鼠/小鼠神经元融合细胞保种中心|STR图谱
L2 Cells大鼠肺上皮细胞保种中心|STR图谱
TE-7 Cells人食管癌细胞保种中心|STR图谱
HDF-a Cells人皮肤成纤维细胞保种中心|STR图谱
INS-1 Cells大鼠胰岛细胞瘤细胞保种中心|STR图谱
WEHI3 Cells;背景说明：白血病；BALB/c;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：悬浮;形态特性：详见产品说明书;相关产品有：Hs294T细胞、RPMI-7951细胞、SGC7901/DDP细胞
RenCa Cells;背景说明：详见相关文献介绍;传代方法：１：２传代;生长特性：贴壁生长;形态特性：上皮细胞样;相关产品有：NIE 115细胞、SVOG细胞、MT-2细胞
U-251 MG Cells;背景说明：U-２５１ MG分离至一位患者的胶质母细胞瘤组织。;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：成纤维细胞样;相关产品有：AML-EOL-1细胞、AMO1细胞、PC615.3细胞
MESSA Cells;背景说明：详见相关文献介绍;传代方法：１：６-１：８传代；每周２-３次。;生长特性：贴壁生长;形态特性：成纤维细胞样　;相关产品有：M109细胞、KYSE-70细胞、L1210细胞
H-2330 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明书部分;形态特性：详见产品说明书;相关产品有：Soleus clone 8细胞、RL-952细胞、HEK293FT细胞
CCD-33Co Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明书部分;形态特性：详见产品说明书;相关产品有：HMC细胞、SKNEP-1细胞、SBC3细胞
MD Anderson-Metastatic Breast-231 Cells;背景说明：MDA-MB-２３１来自患有转移乳腺腺癌的５１岁女病人的胸水。在裸鼠和ALS处理的BALB/c小鼠中，它能形成低分化腺癌（III级）。;传代方法：消化３-５分钟，１：２,３天内可长满;生长特性：贴壁生长;形态特性：上皮样;相关产品有：95D细胞、Hs 940.T细胞、UACC812细胞
OCM-1A-RFP Cells人眼脉络黑色素瘤细胞保种中心|STR图谱
HCe-8693 Cells人盲肠腺癌细胞保种中心|STR图谱
LUVA Cells人肥大细胞保种中心|STR图谱
Hs 578Bst Cells人正常乳腺细胞保种中心|STR图谱
AMC-HN-8 Cells人喉癌细胞保种中心|STR图谱
LN-229 Cells人胶质瘤细胞保种中心|STR图谱
HeLa-Luc Cells人宫颈癌细胞保种中心|STR图谱
RBMVEC Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明书部分;形态特性：详见产品说明书;相关产品有：DoTc2 4510细胞、G401细胞、IPLB-SF-21-AE细胞
HPSI0516i-iool_6 Cells(提供STR鉴定图谱)
KaMi Cells(提供STR鉴定图谱)
Mel-CV Cells(提供STR鉴定图谱)
NH50293 Cells(提供STR鉴定图谱)
SSMUe005-A Cells(提供STR鉴定图谱)
ME-180 Cells人子宫颈表皮癌细胞保种中心|STR图谱
NCI-H1417 Cells人小细胞肺癌细胞保种中心|STR图谱
R456 Cells(提供STR鉴定图谱)
Ubigene HCT 116 EDA KO Cells(提供STR鉴定图谱)
VUi023-A Cells(提供STR鉴定图谱)
HG01102 Cells(提供STR鉴定图谱)
BOWES Cells;背景说明：详见相关文献介绍;传代方法：１：６—１：１０传代，２天换液１次;生长特性：贴壁生长;形态特性：上皮细胞;相关产品有：T 24细胞、MDA 435细胞、3T3-A31细胞
CT26-clone 25 Cells;背景说明：结肠癌； BALB/c;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明书;相关产品有：MRCV细胞、Hce8693细胞、SF 539细胞
R 2 C Cells;背景说明：睾丸间质瘤；雄性；Wistar Furth;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明书;相关产品有：CCD-841-CoTr细胞、MDA-468细胞、HCEC-12细胞
R 1610 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明书部分;形态特性：详见产品说明书;相关产品有：E0771细胞、PA1细胞、MLE12细胞
End1/E6E7 Cells人子宫内膜异位症上皮细胞保种中心|STR图谱
EL4 Cells小鼠淋巴瘤细胞保种中心|STR图谱
RENCA+luc Cells小鼠肾癌细胞保种中心|STR图谱
Caki-2-Luc Cells人肾透明细胞癌细胞保种中心|STR图谱
SK-MES-1 Cells人肺鳞癌细胞保种中心|STR图谱
HT-1376 Cells人膀胱癌细胞保种中心|STR图谱
HMCB Cells;背景说明：详见相关文献介绍;传代方法：１：６—１：１０传代，２天换液１次;生长特性：贴壁生长;形态特性：上皮细胞;相关产品有：Madin-Darby Bovine Kidney细胞、MDCKII-WT细胞、NPC-TW 01细胞
Walker-256-TC Cells;背景说明：乳腺癌；雌性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明书;相关产品有：CWR22R细胞、EFM192细胞、MV(4;11)细胞
NCI-H128 Cells;背景说明：小细胞肺癌；胸腔积液转移；男性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明书;相关产品有：UO.31细胞、YTMLC-90细胞、GM03573A细胞
NCI-H128 Cells;背景说明：小细胞肺癌；胸腔积液转移；男性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明书;相关产品有：UO.31细胞、YTMLC-90细胞、GM03573A细胞
NCI-H1618 Cells;背景说明：详见相关文献介绍;传代方法：３-４天换液１次。;生长特性：悬浮生长;形态特性：详见产品说明书;相关产品有：3396细胞、H-1417细胞、SNU-1细胞
UCLA SO M21 Cells;背景说明：黑色素瘤；女性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明书;相关产品有：MAVER-1细胞、Mono Mac 6细胞、SF-295细胞
TM4 Cells小鼠睾丸Sertoli细胞保种中心|STR图谱
Hepa 1-6 Cells小鼠肝癌细胞保种中心|STR图谱
IB-RS-2 Cells猪肾细胞保种中心|STR图谱
KMH-2 Cells人甲状腺癌细胞保种中心|STR图谱
RAW 264.7-Luc Cells小鼠单核巨噬细胞白血病细胞保种中心|STR图谱
L2 Cells大鼠肺上皮细胞保种中心|STR图谱
CAL-62 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明书部分;形态特性：详见产品说明书;相关产品有：mRMEC细胞、KYSE180细胞、HS766T细胞
MH-S Cells;背景说明：巨噬细胞；雄性；SV４０转化；BALB/cJ;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：悬浮;形态特性：详见产品说明书;相关产品有：Stanford University-Diffuse Histiocytic Lymphoma-1细胞、PC12(高分化)细胞、KE39细胞
MDA134 Cells;背景说明：该细胞１９７３年由R. Cailleau建系，源自７４岁乳腺导管癌女性患者的胸腔积液，细胞生长缓慢，松散贴壁，生长过程中会脱落到培养基，不会汇合，过表达FGF受体;传代方法：１：２—１：４传代，每周换液２—３次;生长特性：松散贴壁生长;形态特性：上皮细胞样;相关产品有：RBL 1细胞、H-1993细胞、MDCK细胞
KYSE 410 Cells;背景说明：食管鳞癌；男性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明书;相关产品有：ZR7530细胞、Dysplastic Oral Keratinocyte细胞、786.O细胞
NCI-H1436 Cells;背景说明：详见相关文献介绍;传代方法：随细胞的密度而增加;生长特性：悬浮生长;形态特性：详见产品说明书;相关产品有：LNCaP FGC细胞、V79细胞、H2087细胞
A7r5 Cells大鼠胸大动脉平滑肌细胞保种中心|STR图谱
RS1 Cells大鼠皮肤成纤维样细胞保种中心|STR图谱
SW1417 Cells人结肠直肠腺癌细胞保种中心|STR图谱
MRC-5 Cells人胚肺细胞保种中心|STR图谱
AAV-293 Cells人胚肾细胞保种中心|STR图谱
Ku812 Cells人外周血嗜碱性白血病细胞保种中心|STR图谱
CL-11 Cells人结肠癌细胞保种中心|STR图谱
STC-1 Cells;背景说明：STC-１细胞来源于双重转基因小鼠的肠肿瘤组织。含有连接大鼠胰岛素基因启动子与多瘤病毒小T抗原的融合基因与含有连接大鼠胰岛素基因与SV４０的基因结合产生双转基因小鼠。这些小鼠一般患有肠肿瘤以及胰腺β细胞瘤。STC-１细胞产生激素分泌素。;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：上皮细胞样;相关产品有：Tu-686细胞、P3-NS1/1Ag 4.1细胞、NIH/3T3细胞
Ontario Cancer Institute-Acute Myeloid Leukemia-4 Cells;背景说明：急性髓系白血病；女性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：悬浮;形态特性：详见产品说明书;相关产品有：Hs 294T细胞、U-118MG细胞、HNE-1细胞
SK MES 1 Cells;背景说明：源于一位６５岁患有肺鳞状细胞癌的白人男性，自转移性胸腔积液分离而来。;传代方法：１：２传代;生长特性：贴壁生长;形态特性：上皮样;相关产品有：OVCAR.3细胞、D-283MED细胞、LNCaP C4-2细胞
NCI-HUT-292 Cells;背景说明：详见相关文献介绍;传代方法：１：３-１：８传代；２-３天换液１次。;生长特性：贴壁生长;形态特性：上皮样;相关产品有：NCIH2291细胞、H322T细胞、SUDHL4细胞
MDA231 Cells;背景说明：MDA-MB-２３１来自患有转移乳腺腺癌的５１岁女病人的胸水。在裸鼠和ALS处理的BALB/c小鼠中，它能形成低分化腺癌（III级）。;传代方法：消化３-５分钟，１：２,３天内可长满;生长特性：贴壁生长;形态特性：上皮样;相关产品有：JURKAT E-61细胞、Panc813细胞、KU-812细胞
U251n Cells;背景说明：U-２５１ MG分离至一位患者的胶质母细胞瘤组织。;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：成纤维细胞样;相关产品有：IM-9细胞、NCIH748细胞、H-1672细胞
CMT-64 Cells;背景说明：肺腺癌；雌性；C５７;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明书;相关产品有：GP2d细胞、tdott细胞、UMNSAH-DF1细胞
Virginia Mason Research Center-Renal Cancer Z Cells;背景说明：详见相关文献介绍;传代方法：１：６传代;生长特性：贴壁生长;形态特性：上皮细胞;相关产品有：MDA-PCa-2b细胞、HT-22细胞、293FT细胞
"    "PubMed=4321974
Maurer B.A., Imamura T., Wilbert S.M.
Incidence of EB virus-containing cells in primary and secondary clones of several Burkitt lymphoma cell lines.
Cancer Res. 30:2870-2875(1970)

PubMed=4122458; DOI=10.1002/ijc.2910100108
Klein G., Dombos L., Gothoskar B.
Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus.
Int. J. Cancer 10:44-57(1972)

PubMed=5021706; PMCID=PMC1407864
van Furth R., Gorter H., Nadkarni J.S., Nadkarni J.J., Klein E., Clifford P.
Synthesis of immunoglobulins by biopsied tissues and cell lines from Burkitt's lymphoma.
Immunology 22:847-857(1972)

PubMed=4364259; DOI=10.1002/ijc.2910110210
Klein G., Dombos L.
Relationship between the sensitivity of EBV-carrying lymphoblastoid lines to superinfection and the inducibility of the resident viral genome.
Int. J. Cancer 11:327-337(1973)

PubMed=170370; DOI=10.1099/0022-1317-28-2-207
Adams A., Strander H., Cantell K.
Sensitivity of the Epstein-Barr virus transformed human lymphoid cell lines to interferon.
J. Gen. Virol. 28:207-217(1975)

PubMed=216485
Higgins N.P., Strauss B.S.
Differences in the ability of human lymphoblastoid lines to exclude bromodeoxyuridine and in their sensitivity to methyl methanesulfonate and to incorporated [3H]thymidine.
Cancer Res. 39:312-320(1979)

PubMed=7316467; DOI=10.1111/j.1469-1809.1980.tb00953.x
Povey S., Jeremiah S., Arthur E., Steel M., Klein G.
Differences in genetic stability between human cell lines from patients with and without lymphoreticular malignancy.
Ann. Hum. Genet. 44:119-133(1980)

PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=6286763; DOI=10.4049/jimmunol.129.3.1336
Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd-Kulikowsk H.D., Parsons R.G.
Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type.
J. Immunol. 129:1336-1342(1982)

PubMed=6806672; DOI=10.1038/298474a0
Lenoir G.M., Preud'homme J.-L., Bernheim A., Berger R.
Correlation between immunoglobulin light chain expression and variant translocation in Burkitt's lymphoma.
Nature 298:474-476(1982)

PubMed=6954533; DOI=10.1073/pnas.79.7.2194; PMCID=PMC346157
Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A., Aaronson S.A., Wong-Staal F.
Differential expression of the amv gene in human hematopoietic cells.
Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982)

PubMed=6186604; DOI=10.1007/BF00364753
de Preval C., Mach B.
The absence of beta 2-microglobulin in Daudi cells: active gene but inactive messenger RNA.
Immunogenetics 17:133-140(1983)

PubMed=11894933; DOI=10.1002/j.1460-2075.1983.tb01412.x; PMCID=PMC555120
Rosa F.M., Berissi H., Weissenbach J., Maroteaux L., Fellous M., Revel M.
The beta2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon.
EMBO J. 2:239-243(1983)

PubMed=6200433; DOI=10.1007/BF00364762
Brodsky F.M.
A matrix approach to human class II histocompatibility antigens: reactions of four monoclonal antibodies with the products of nine haplotypes.
Immunogenetics 19:179-194(1984)

PubMed=6231253; DOI=10.1002/ijc.2910330407
Ehlin-Henriksson B., Klein G.
Distinction between Burkitt lymphoma subgroups by monoclonal antibodies: relationships between antigen expression and type of chromosomal translocation.
Int. J. Cancer 33:459-463(1984)

PubMed=6500159; DOI=10.1159/000163283
Gershwin M.E., Lentz D., Owens R.B.
Relationship between karyotype of tissue culture lines and tumorigenicity in nude mice.
Exp. Cell Biol. 52:361-370(1984)

PubMed=6547209; DOI=10.1038/309592a0
Rabbitts T.H., Forster A., Hamlyn P.H., Baer R.
Effect of somatic mutation within translocated c-myc genes in Burkitt's lymphoma.
Nature 309:592-597(1984)

PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=6592381; DOI=10.1093/jnci/73.4.841
Favrot M.-C., Philip I., Philip T., Portoukalian J., Dore J.-F., Lenoir G.M.
Distinct reactivity of Burkitt's lymphoma cell lines with eight monoclonal antibodies correlated with the ethnic origin.
J. Natl. Cancer Inst. 73:841-847(1984)

PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- 1 carboxylic esterase.
Leuk. Res. 9:209-229(1985)

PubMed=2998993
Steel C.M., Morten J.E.N., Foster E.
The cytogenetics of human B lymphoid malignancy: studies in Burkitt's lymphoma and Epstein-Barr virus-transformed lymphoblastoid cell lines.
IARC Sci. Publ. 60:265-292(1985)

PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- III Beta-hexosaminidase (E.C. 3.2.1.30).
Leuk. Res. 9:549-559(1985)

PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.
Leuk. Res. 9:537-548(1985)

PubMed=3905596
Favrot M.-C., Philip I., Philip T., Cabrillat H., Pinatel C., Dore J.-F., Lenoir G.M.
Immunophenotypic classification of 28 Burkitt cell lines with monoclonal antibodies and reagent selection for bone-marrow purging.
IARC Sci. Publ. 60:447-452(1985)

PubMed=3080238
Sieverts H., Alabaster O., Goldschmidts W., Magrath I.T.
Expression of surface antigens during the cell cycle in different growth phases of American and African Burkitt's lymphoma cell lines.
Cancer Res. 46:1182-1188(1986)

PubMed=3100061; DOI=10.1016/0008-8749(86)90099-7
Benjamin D., Bazar L.S., Wallace B., Jacobson R.J.
Heterogeneity of B-cell growth factor receptor reactivity in healthy donors and in patients with chronic lymphatic leukemia: relationship to B-cell-derived lymphokines.
Cell. Immunol. 103:394-408(1986)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3785169; DOI=10.1128/mcb.6.5.1374-1378.1986; PMCID=PMC367660
Dron M., Modjtahedi N., Brison O., Tovey M.G.
Interferon modulation of c-myc expression in cloned Daudi cells: relationship to the phenotype of interferon resistance.
Mol. Cell. Biol. 6:1374-1378(1986)

PubMed=3026973; DOI=10.1002/ijc.2910390215
Ehlin-Henriksson B., Manneborg-Sandlund A., Klein G.
Expression of B-cell-specific markers in different Burkitt lymphoma subgroups.
Int. J. Cancer 39:211-218(1987)

PubMed=3034807; DOI=10.1002/ijc.2910390622
Ohno H., Fukuhara S., Takahashi R., Mihara K.-i., Sugiyama T., Doi S., Uchino H., Toyoshima K.
c-yes and bcl-2 genes located on 18q21.3 in a follicular lymphoma cell line carrying a t(14;18) chromosomal translocation.
Int. J. Cancer 39:785-788(1987)

PubMed=3116544; DOI=10.1073/pnas.84.19.6835; PMCID=PMC299179
Haluska F.G., Tsujimoto Y., Croce C.M.
The t(8;14) chromosome translocation of the Burkitt lymphoma cell line Daudi occurred during immunoglobulin gene rearrangement and involved the heavy chain diversity region.
Proc. Natl. Acad. Sci. U.S.A. 84:6835-6839(1987)

PubMed=2470097; DOI=10.1073/pnas.86.9.3257; PMCID=PMC287109
Shtivelman E., Henglein B., Groitl P., Lipp M., Bishop J.M.
Identification of a human transcription unit affected by the variant chromosomal translocations 2;8 and 8;22 of Burkitt lymphoma.
Proc. Natl. Acad. Sci. U.S.A. 86:3257-3260(1989)

PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x
Nakano A., Harada T., Morikawa S., Kato Y.
Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.
Acta Pathol. Jpn. 40:107-115(1990)

PubMed=2052620; DOI=10.1073/pnas.88.12.5413; PMCID=PMC51883
Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.
p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.
Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991)

CLPUB00447
Mulivor R.A., Suchy S.F.
1992/1993 catalog of cell lines. NIGMS human genetic mutant cell repository. 16th edition. October 1992.
(In misc. document) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda; USA (1992)

PubMed=1325212; DOI=10.1182/blood.V80.5.1289.1289
Benjamin D., Knobloch T.J., Dayton M.A.
Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10.
Blood 80:1289-1298(1992)

PubMed=8301159; DOI=10.1089/jir.1993.13.377
Dron M., Tovey M.G.
Interferon-resistant Daudi cells are deficient in interferon-alpha-induced ISGF3 alpha activation, but remain sensitive to the interferon-alpha-induced increase in ISGF3 gamma content.
J. Interferon Res. 13:377-383(1993)

PubMed=8515068; DOI=10.4049/jimmunol.150.12.5418
Jain V.K., Judde J.-G., Max E.E., Magrath I.T.
Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
J. Immunol. 150:5418-5428(1993)

PubMed=8176200; DOI=10.4049/jimmunol.152.10.4749
Benjamin D., Sharma V., Knobloch T.J., Armitage R.J., Dayton M.A., Goodwin R.G.
B cell IL-7. Human B cell lines constitutively secrete IL-7 and express IL-7 receptors.
J. Immunol. 152:4749-4757(1994)

PubMed=8197130; DOI=10.1073/pnas.91.11.4751; PMCID=PMC43866
Bicknell D.C., Rowan A.J., Bodmer W.F.
Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors.
Proc. Natl. Acad. Sci. U.S.A. 91:4751-4755(1994)

PubMed=7849311; DOI=10.1182/blood.V85.4.893.bloodjournal854893
Stranks G., Height S.E., Mitchell P., Jadayel D.M., Yuille M.A.R., De Lord C.F.M., Clutterbuck R.D., Treleaven J.G., Powles R.L., Nacheva E., Oscier D.G., Karpas A., Lenoir G.M., Smith S.D., Millar J.L., Catovsky D., Dyer M.J.S.
Deletions and rearrangement of CDKN2 in lymphoid malignancy.
Blood 85:893-901(1995)

PubMed=8558913
Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M., Imaizumi M., Endo M., Takano N., Konno T.
Cell surface c-kit receptors in human leukemia cell lines and pediatric leukemia: selective preservation of c-kit expression on megakaryoblastic cell lines during adaptation to in vitro culture.
Leukemia 10:102-105(1996)

PubMed=8558920
Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M., Quentmeier H., Drexler H.G.
The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.
Leukemia 10:142-149(1996)

PubMed=8568269; DOI=10.4049/jimmunol.156.4.1626
Benjamin D., Sharma V., Kubin M., Klein J.L., Sartori A., Holliday J., Trinchieri G.
IL-12 expression in AIDS-related lymphoma B cell lines.
J. Immunol. 156:1626-1637(1996)

PubMed=8847894
Tani A., Tatsumi E., Nakamura F., Kumagai S., Kosaka Y., Sano K., Nakamura H., Amakawa R., Ohno H.
Sensitivity to dexamethasone and absence of bcl-2 protein in Burkitt's lymphoma cell line (Black93) derived from a patient with acute tumor lysis syndrome: comparative study with other BL and non-BL lines.
Leukemia 10:1592-1603(1996)

PubMed=9192833
Cherney B.W., Bhatia K.G., Sgadari C., Gutierrez M.I., Mostowski H.S., Pike S.E., Gupta G., Magrath I.T., Tosato G.
Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells.
Cancer Res. 57:2508-2515(1997)

PubMed=9473234; DOI=10.1182/blood.V91.5.1680
Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.
p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma.
Blood 91:1680-1687(1998)

PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x; PMCID=PMC5921588
Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y., Hirai H.
Frameshift mutations of the hMSH6 gene in human leukemia cell lines.
Jpn. J. Cancer Res. 89:33-39(1998)

PubMed=9685479; DOI=10.1093/nar/26.16.3651; PMCID=PMC147775
Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T., Roos G.
Telomere analysis by fluorescence in situ hybridization and flow cytometry.
Nucleic Acids Res. 26:3651-3656(1998)

PubMed=9737686; DOI=10.1038/sj.leu.2401112
Zhang W.-J., Ohnishi K., Shigeno K., Fujisawa S., Naito K., Nakamura S., Takeshita K., Takeshita A., Ohno R.
The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.
Leukemia 12:1383-1391(1998)

PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x; PMCID=PMC5921886
Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T., Aizawa Y., Ueda R., Seto M.
Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.
Jpn. J. Cancer Res. 89:712-718(1998)

PubMed=9973220
Gutierrez M.I., Cherney B.W., Hussain A., Mostowski H.S., Tosato G., Magrath I.T., Bhatia K.G.
Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis.
Cancer Res. 59:696-703(1999)

PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.
Leuk. Res. 24:255-262(2000)

PubMed=11021758; DOI=10.1038/sj.leu.2401891
Majka M., Rozmyslowicz T., Honczarenko M.J., Ratajczak J., Wasik M.A., Gaulton G.N., Ratajczak M.Z.
Biological significance of the expression of HIV-related chemokine coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic cell lines.
Leukemia 14:1821-1832(2000)

PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000), 255-262.
Leuk. Res. 25:275-278(2001)

PubMed=12145705; DOI=10.1038/sj.leu.2402519
Langerak A.W., Moreau E.J., van Gastel-Mol E.J., van der Burg M., van Dongen J.J.M.
Detection of clonal EBV episomes in lymphoproliferations as a diagnostic tool.
Leukemia 16:1572-1573(2002)

PubMed=12967475; DOI=10.1111/j.1349-7006.2003.tb01518.x; PMCID=PMC11160262
Maesako Y., Uchiyama T., Ohno H.
Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B-cell lymphoma.
Cancer Sci. 94:774-781(2003)

PubMed=14504097; DOI=10.1182/blood-2003-02-0418
Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R., Tsuchida M., Sugita K., Ida K., Hayashi Y.
FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
Blood 103:1085-1088(2004)

PubMed=15028022; DOI=10.1111/j.1440-1827.2004.01612.x
Kamimura K., Hojo H., Abe M.
Characterization of expression of protein kinase C isozymes in human B-cell lymphoma: relationship between its expression and prognosis.
Pathol. Int. 54:224-230(2004)

PubMed=19358282; DOI=10.1002/ijc.24351
Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M., Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.
Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
Int. J. Cancer 125:212-221(2009)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20454443; DOI=10.1155/2010/904767; PMCID=PMC2861168
Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22885699; DOI=10.1038/nature11378; PMCID=PMC3609867
Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W.-M., Zhang M.-L., Wright G., Shaffer A.L. 3rd, Hodson D.J., Buras E., Liu X.-L., Powell J.I., Yang Y.-D., Xu W.-H., Zhao H., Kohlhammer H., Rosenwald A., Kluin P.M., Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.-C., Pittaluga S., Wilson W., Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
Nature 490:116-120(2012)

PubMed=24590883; DOI=10.1002/gcc.22161
Murga Penas E.-M., Schilling G., Behrmann P., Klokow M., Vettorazzi E., Bokemeyer C., Dierlamm J.
Comprehensive cytogenetic and molecular cytogenetic analysis of 44 Burkitt lymphoma cell lines: secondary chromosomal changes characterization, karyotypic evolution, and comparison with primary samples.
Genes Chromosomes Cancer 53:497-515(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25355872; DOI=10.1128/JVI.02570-14; PMCID=PMC4301145
Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z., O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.
High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.
J. Virol. 89:713-729(2015)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29892436; DOI=10.1098/rsos.172472; PMCID=PMC5990783
Shioda S., Kasai F., Watanabe K., Kawakami K., Ohtani A., Iemura M., Ozawa M., Arakawa A., Hirayama N., Kawaguchi E., Tano T., Miyata S., Satoh M., Shimizu N., Kohara A.
Screening for 15 pathogenic viruses in human cell lines registered at the JCRB Cell Bank: characterization of in vitro human cells by viral infection.
R. Soc. Open Sci. 5:172472-172472(2018)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5; PMCID=PMC6167786
Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.H., Koeffler H.P.
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
BMC Cancer 18:940.1-940.13(2018)

PubMed=30629668; DOI=10.1371/journal.pone.0210404; PMCID=PMC6328144
Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.
Screening human cell lines for viral infections applying RNA-Seq data analysis.
PLoS ONE 14:E0210404-E0210404(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)"